Trials / Completed
CompletedNCT00061022
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,200 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NXY-059 |
Timeline
- Start date
- 2003-05-01
- Primary completion
- 2006-09-01
- Completion
- 2006-09-01
- First posted
- 2003-05-21
- Last updated
- 2010-11-15
Locations
256 sites across 30 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hong Kong, Hungary, Israel, Mexico, New Zealand, Philippines, Poland, Portugal, Russia, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00061022. Inclusion in this directory is not an endorsement.